Last reviewed · How we verify
OCTA-C1-INH
OCTA-C1-INH is a recombinant C1-esterase inhibitor that replaces or augments deficient or dysfunctional C1-inhibitor protein to prevent excessive complement and contact system activation.
OCTA-C1-INH is a recombinant C1-esterase inhibitor that replaces or augments deficient or dysfunctional C1-inhibitor protein to prevent excessive complement and contact system activation. Used for Hereditary angioedema (HAE) due to C1-inhibitor deficiency or dysfunction.
At a glance
| Generic name | OCTA-C1-INH |
|---|---|
| Sponsor | Octapharma |
| Drug class | Recombinant C1-esterase inhibitor |
| Target | C1-esterase inhibitor (C1-INH) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rare Disease |
| Phase | Phase 3 |
Mechanism of action
C1-inhibitor is a serine protease inhibitor that regulates the classical complement pathway and contact system (kallikrein-kinin pathway). Deficiency or dysfunction of C1-INH leads to uncontrolled activation of these cascades, resulting in excessive bradykinin production and angioedema. OCTA-C1-INH restores normal inhibitory control, preventing acute attacks and reducing swelling episodes.
Approved indications
- Hereditary angioedema (HAE) due to C1-inhibitor deficiency or dysfunction
Common side effects
- Thrombosis / thromboembolic events
- Injection site reactions
- Headache
- Hypersensitivity reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OCTA-C1-INH CI brief — competitive landscape report
- OCTA-C1-INH updates RSS · CI watch RSS
- Octapharma portfolio CI